ArticleNucleic acids research2012
Chimeric piggyBac transposases for genomic targeting in human cells.
Article in Nucleic acids research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Mining and engineering of activeSynthetic and systems biotechnology · 2027Article
- Programmable enzymes for targeted gene insertion.Nature reviews. Genetics · 2026Review
- Retargeted serine integrases for one-step, precise integration of large DNA sequences in human cells.Nature biotechnology · 2026Article
- Engineered NLS-PBase system boosts stability and productivity in recombinant cell lines.Bioresources and bioprocessing · 2026Article
- Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposase.Nucleic acids research · 2025Article
- Systematic optimization of prime editing for enhanced efficiency and versatility in genome engineering across diverse cell types.Frontiers in cell and developmental biology · 2025Article
- Gene editing and its applications in biomedicine.Science China. Life sciences · 2022Review
- Transposase-CRISPR mediated targeted integration (TransCRISTI) in the human genome.Scientific reports · 2022Article
- The large bat Helitron DNA transposase forms a compact monomeric assembly that buries and protects its covalently bound 5'-transposon end.Molecular cell · 2021Article
- An Engineered Cas-Transposon System for Programmable and Site-Directed DNA Transpositions.The CRISPR journal · 2019Article
- Targeted DNA transposition in vitro using a dCas9-transposase fusion protein.Nucleic acids research · 2019Article
- RNA-guidedSynthetic biology (Oxford, England) · 2019Article
- Article
- Preclinical and clinical advances in transposon-based gene therapy.Bioscience reports · 2017Review
- A PiggyBac mediated approach for lactoferricin gene transfer in bovine mammary epithelial stem cells for management of bovine mastitis.Oncotarget · 2017Article
- Comparative analysis of chimeric ZFP-, TALE- and Cas9-piggyBac transposases for integration into a single locus in human cells.Nucleic acids research · 2017Article
- Engineering and Application of Zinc Finger Proteins and TALEs for Biomedical Research.Molecules and cells · 2017Review
- DNA Transposition at Work.Chemical reviews · 2016Review
- Vast potential for using the piggyBac transposon to engineer transgenic plants at specific genomic locations.Bioengineered · 2016Article
- piggyBac-ing models and new therapeutic strategies.Trends in biotechnology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Integrating vectors such as viruses and transposons insert transgenes semi-randomly and can potentially disrupt or deregulate genes. For these techniques to be of therapeutic value, a method for controlling the precise location of insertion is required. The piggyBac (PB) transposase is an efficient gene transfer vector active in a variety of cell types and proven to be amenable to modification. Here we present the design and validation of chimeric PB proteins fused to the Gal4 DNA binding domain with the ability to target transgenes to pre-determined sites. Upstream activating sequence (UAS) Gal4 recognition sites harbored on recipient plasmids were preferentially targeted by the chimeric Gal4-PB transposase in human cells. To analyze the ability of these PB fusion proteins to target chromosomal locations, UAS sites were randomly integrated throughout the genome using the Sleeping Beauty transposon. Both N- and C-terminal Gal4-PB fusion proteins but not native PB were capable of targeting transposition nearby these introduced sites. A genome-wide integration analysis revealed the ability of our fusion constructs to bias 24% of integrations near endogenous Gal4 recognition sequences. This work provides a powerful approach to enhance the properties of the PB system for applications such as genetic engineering and gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.